Untangling the Role of MYC in Sarcomas and Its Potential as a Promising Therapeutic Target
Open Access
- 25 February 2025
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (5) , 1973
Abstract
MYC plays a pivotal role in the biology of various sarcoma subtypes, acting as a key regulator of tumor growth, proliferation, and metabolic reprogramming. This oncogene is frequently dysregulated across different sarcomas, where its expression is closely intertwined with the molecular features unique to each subtype. MYC interacts with critical pathways such as cell cycle regulation, apoptosis, and angiogenesis, amplifying tumor aggressiveness and resistance to standard therapies. Furthermore, MYC influences the tumor microenvironment by modulating cell–extracellular matrix interactions and immune evasion mechanisms, further complicating therapeutic management. Despite its well-established centrality in sarcoma pathogenesis, targeting MYC directly remains challenging due to its “undruggable” protein structure. However, emerging therapeutic strategies, including indirect MYC inhibition via epigenetic modulators, transcriptional machinery disruptors, and metabolic pathway inhibitors, offer new hope for sarcoma treatment. This review underscores the importance of understanding the intricate roles of MYC across sarcoma subtypes to guide the development of effective targeted therapies. Given MYC’s central role in tumorigenesis and progression, innovative approaches aiming at MYC inhibition could transform the therapeutic landscape for sarcoma patients, providing a much-needed avenue to overcome therapeutic resistance and improve clinical outcomes.Keywords
This publication has 231 references indexed in Scilit:
- Cellular senescence and metabolic reprogramming: Unraveling the intricate crosstalk in the immunosuppressive tumor microenvironmentCancer Communications, 2024
- Antitumor Effect of Anti‐c‐Myc Aptamer‐Based PROTAC for Degradation of the c‐Myc ProteinAdvanced Science, 2024
- Integrated multi‐omics profiling of high‐grade estrogen receptor‐positive, HER2‐negative breast cancerMolecular Oncology, 2021
- Ultra‐rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entitiesCancer, 2021
- Transposable element insertion as a mechanism of SMARCB1 inactivation in atypical teratoid/rhabdoid tumorGenes, Chromosomes and Cancer, 2021
- Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomasCancer, 2021
- Inhibition of MYC attenuates tumor cell self‐renewal and promotes senescence in SMARCB1‐deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivoInternational Journal of Cancer, 2019
- 12‐O‐tetradecanoylphorbol‐13‐acetate and EZH2 inhibition: A novel approach for promoting myogenic differentiation in embryonal rhabdomyosarcoma cellsJournal of Cellular Physiology, 2017
- Declining childhood and adolescent cancer mortalityCancer, 2014
- Atypical teratoid rhabdoid tumor: improved long‐term survival with an intensive multimodal therapy and delayed radiotherapy. The Medical University of Vienna Experience 1992–2012Cancer Medicine, 2013